Written by the Nuvirox Research Team
- Turmeric and its active compound curcumin can affect platelet function and may interact with the CYP3A4/P-glycoprotein pathway apixaban relies on, which is why drug-interaction databases flag this as a moderate interaction.
- Human evidence is mixed and thin: a small clinical study found a specific curcumin formulation didn't change INR or bleeding time in stable patients, but at least one published case report describes a serious bleeding event in a patient on apixaban plus clopidogrel who started curcumin.
- This is a decision for you and your prescriber, not a supplement label — disclose any turmeric or curcumin product to whoever manages your anticoagulation before you start.
Short answer: turmeric and curcumin can plausibly interact with Eliquis (apixaban), and the honest reading of the evidence is "talk to your doctor before combining them," not "it's fine" or "never touch it." Apixaban is metabolized in part through the CYP3A4 enzyme and P-glycoprotein transporter, and curcumin has documented effects on both pathways, plus independent effects on platelet function. The clinical data are limited and mixed — one study found no measurable effect on anticoagulation markers, while a case report describes a serious bleeding event in a patient combining curcumin with apixaban and clopidogrel. Because apixaban's entire job is preventing dangerous clotting, this is exactly the kind of interaction question that belongs in a conversation with your prescriber, not something to self-manage from a supplement bottle.
Why would turmeric interact with a blood thinner at all?
Turmeric's interaction potential comes from two mechanisms: curcumin's effect on platelets, and its effect on the liver enzymes and transporters that process apixaban. Curcumin has been studied for antiplatelet and anti-thrombotic activity in laboratory and animal models, meaning it may independently reduce the blood's ability to clot — adding to, not replacing, what apixaban already does. Separately, apixaban is partly metabolized by the CYP3A4 enzyme and moved across cell membranes by the P-glycoprotein (P-gp) transporter, and curcumin interacts with both systems, though not in a simple, one-directional way. Curcumin itself is poorly absorbed on its own, which is part of why its real-world pharmacokinetic effect depends heavily on the formulation and dose.
Does curcumin inhibit or activate the enzyme apixaban depends on?
Research shows curcumin can do both, depending on dose and whether you're looking at the parent compound or its metabolites — which is exactly why this interaction is hard to predict from a label. A study published in Scientific Reports found that while purified curcumin inhibited CYP3A4 activity in laboratory (in vitro) testing, oral curcumin taken by rats produced metabolites that markedly activated CYP3A4 in the body, and this activation "overrode" the inhibition seen with the pure compound, cutting the bioavailability of a co-administered CYP3A4-metabolized drug by roughly 70% (Hsieh et al., 2014, Scientific Reports). That paradox matters: curcumin's real-world effect on a CYP3A4 substrate like apixaban could theoretically push toward higher drug exposure (more anticoagulant effect, more bleeding risk) or lower exposure (less protection), depending on dose and duration. Neither direction is reassuring for someone relying on a precise anticoagulant dose to prevent stroke or clot.
How is turmeric flagged in interaction-checker databases?
Standard clinical drug-interaction references classify the turmeric-apixaban interaction as moderate, with the primary concern being additive bleeding risk from curcumin's effect on platelet function. The stated mechanism is that turmeric and curcumin may affect platelet function and clotting, increasing bleeding risk when combined with a blood thinner like apixaban. A "moderate" classification generally means the interaction is plausible and clinically relevant but not an absolute contraindication — it calls for physician awareness and monitoring rather than automatic avoidance, but it's not something to wave off as harmless either.
Illustrative diagram, not plotted from a specific dataset. It summarizes two mechanisms discussed in the pharmacology literature, not a measured combined effect.
What human studies actually show
Hu et al. (2018, European Review for Medical and Pharmacological Sciences) tested a bioavailable curcumin formulation (Meriva®) in patients already stable on antiplatelet agents (aspirin, ticlopidine, or clopidogrel, for at least two years) or on the anticoagulants warfarin or dabigatran. After 10 days, there was no significant change in bleeding time in the antiplatelet group and no significant change in INR in the anticoagulant group, and researchers concluded the formulation "does not interfere" with these medications' activity in stable patients (PMID: 30070343). This is the most relevant human interaction data available, but it has real limits: no apixaban arm, only 10–15 days of exposure, and one specific formulation that may not generalize.
A published case report in the Journal of Clinical Images and Medical Case Reports (2022, Vol. 3, Issue 11) describes a 74-year-old man on chronic apixaban (5 mg twice daily) and clopidogrel who began taking 1 gram of over-the-counter curcumin daily, on a pharmacist's suggestion, for abdominal inflammation. One week later he developed a large spontaneous thigh hematoma, hemoglobin dropping from 12.7 to 8.2 g/dL, requiring transfusion and a 14-day hospitalization, with lasting pain and mobility limitations afterward. A single case report can't establish causation — the patient had multiple bleeding risk factors, including dual antiplatelet/anticoagulant therapy — but it's a real, documented adverse event in the exact combination this article is about.
Survey research by Tarn et al. (2020, Journal of the American Geriatrics Society) found a substantial share of apixaban patients were using over-the-counter products with documented or possible interactions, including turmeric, with limited awareness of the risk (PMID: 31658372). It doesn't measure bleeding outcomes, but it's a useful counterweight: the gap isn't just in the pharmacology, it's whether patients tell their prescribers what they're taking at all. Taken together, this is a small, inconsistent evidence base — one controlled study suggesting no measurable effect over 10 days, one adverse event report in a higher-risk combination-therapy patient, and survey data showing this combination happens often without physician awareness.
What this doesn't tell you (and when to see a doctor)
None of the available research is large enough, apixaban-specific enough, or long enough to say turmeric is either safe or unsafe to combine with Eliquis for everyone. The Meriva study is reassuring but narrow — different drug, different formulation, short duration, already-stable patients. The case report is concerning but singular, and the patient had other risk factors. Neither substitutes for individualized medical guidance. Apixaban is prescribed specifically to prevent stroke or dangerous clotting, and any supplement that shifts bleeding risk in either direction carries real stakes. If you notice unusual bruising, bleeding that won't stop, blood in urine or stool, unusually heavy menstrual bleeding, or sudden painful swelling while taking apixaban and any turmeric or curcumin product, seek medical attention promptly. We can't tell you whether your specific regimen is safe — only your prescribing physician, cardiologist, or a pharmacist with your full medication list can make that call.
What to actually do if you're on Eliquis and considering turmeric
Disclose it before you start, not after. Tell your prescribing physician, cardiologist, or pharmacist that you're taking or considering turmeric or curcumin, including the specific product, dose, and formulation — a raw powder, a standardized extract, and a piperine-enhanced formulation are not pharmacologically interchangeable. Bring the bottle to your appointment if you can, and ask whether additional monitoring makes sense, particularly if you're also on an antiplatelet drug like aspirin or clopidogrel, since that combination is exactly what appeared in the case report above. Don't stop, skip, or adjust your apixaban dose on your own in response to a supplement decision — that call belongs to the prescriber managing your therapy. Watch for the bleeding warning signs above for the first several weeks after starting any new supplement alongside a blood thinner.
Frequently asked questions
Is it the turmeric spice in food, or the supplement, that's the concern?
Almost entirely the supplement. A typical food serving of turmeric delivers a small fraction of the curcumin dose used in the research above, so the pharmacological exposure is very different from a daily capsule.
Can I take turmeric a few hours apart from my apixaban dose to avoid the interaction?
Timing separation reduces gut-level absorption interactions, but it doesn't reliably prevent one that works through liver enzymes (CYP3A4) or platelet function, since those effects can persist well beyond the dosing window. Don't rely on spacing doses apart as a workaround without your prescriber's input.
What if I'm only on apixaban and not also on an antiplatelet drug like aspirin or clopidogrel?
The case report above involved apixaban plus clopidogrel, and dual therapy is a known independent bleeding risk factor, so that patient's risk isn't identical to someone on apixaban alone. That said, the CYP3A4/P-gp and platelet mechanisms are relevant to apixaban on its own too, and the reassuring Meriva study wasn't apixaban-specific either. Either way, this is a conversation for your prescriber, not a self-assessment.
Does BioPerine (black pepper extract) in curcumin supplements make the interaction worse?
Piperine is itself a recognized inhibitor of CYP3A4 and P-glycoprotein and is included specifically to increase curcumin absorption — so a piperine-enhanced product could plausibly raise, not lower, the interaction potential versus plain turmeric powder. This hasn't been directly studied in apixaban patients, but it's worth raising with your prescriber.
Should I just avoid turmeric supplements entirely while on Eliquis?
We can't make that call for you — it depends on your bleeding risk factors and what else you're taking, which your prescriber can weigh in a way a blog article cannot. Starting a curcumin supplement without telling the person managing your anticoagulation is the one choice the evidence above argues clearly against.
Why we formulated Turmeric with BioPerine.
Nuvirox's Turmeric with BioPerine pairs a standardized turmeric curcumin extract with BioPerine® black pepper extract. We include piperine specifically because it's one of the better-studied absorption enhancers for curcumin — plain turmeric on its own is notoriously poorly absorbed. We stand behind it with a 60-day money-back guarantee, long enough to actually evaluate it.
If you're on Eliquis (apixaban) or any other blood thinner, please talk to your prescriber before adding this — or any — turmeric or curcumin supplement. As discussed above, curcumin and the piperine used to enhance its absorption both have documented effects on the pathways involved in anticoagulation, and this is a decision that belongs with the physician managing your anticoagulant therapy.
Learn more about Turmeric with BioPerine →The bottom line
Turmeric and curcumin have plausible, mechanistically supported reasons to interact with Eliquis (apixaban) — through platelet function and the CYP3A4/P-glycoprotein pathway apixaban is metabolized by — and interaction-checker databases classify it as moderate for exactly that reason. The direct human evidence doesn't point in one clean direction: a short controlled study found no measurable change in anticoagulation markers with one curcumin formulation, while a documented case report describes a serious bleeding event in a patient combining curcumin with apixaban and an antiplatelet drug. Neither settles the question for you individually. If you're taking Eliquis and want to add turmeric or curcumin — including a BioPerine-enhanced formulation — disclose it to your prescriber first, watch for bleeding warning signs, and never adjust your dose on your own. For related medication questions, see our overviews of turmeric and NSAID interactions, turmeric and statin interactions, and turmeric side effects generally.
References
- Hsieh YW, Huang CY, Lin HH, et al. Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies. Scientific Reports. 2014;4:6587. DOI: 10.1038/srep06587
- Hu S, Belcaro G, Dugall M, et al. Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®). European Review for Medical and Pharmacological Sciences. 2018;22(15):5042-5046. PMID: 30070343. DOI: 10.26355/eurrev_201808_15647
- Spontaneous bleeding and curcumin: Case report. Journal of Clinical Images and Medical Case Reports. 2022;3(11).
- Tarn DM, Barrientos M, Wang AY, et al. Prevalence and Knowledge of Potential Interactions Between Over-the-Counter Products and Apixaban. Journal of the American Geriatrics Society. 2020;68(1):155-162. PMID: 31658372. DOI: 10.1111/jgs.16193
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.